SCHEMBL7812967

SCHEMBL7812967

Cc1cccc(-c2nc3c(o2)C(=O)c2ccccc2C3=O)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP1 O94782 4/20 0.71
USP19 O94966 2/20 0.71
WDR48 Q8TAF3 1/20 0.71
USP2 O75604 2/20 0.61
USP8 P40818 2/20 0.61
OTUB1 Q96FW1 2/20 0.61
USP36 Q9P275 1/20 0.61
UCHL3 P15374 1/20 0.60
RAB9A P51151 7/20 0.50
SMN1; SMN2 Q16637 6/20 0.50
NPC1 O15118 6/20 0.50
MAPT P10636 5/20 0.50
ALDH1A1 P00352 2/20 0.50
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
HPGD P15428 2/20 0.48
TSHR P16473 1/20 0.48
NOTUM Q6P988 1/20 0.47
KDM4E B2RXH2 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7968066 0.84 USP1 (0.77) USP1USP19WDR48USP2USP8
SCHEMBL19220488 0.84 USP1 (0.66) USP1USP19WDR48USP2USP8
SCHEMBL29629184 0.84 USP1 (1.00) USP1USP19WDR48USP2USP8
SCHEMBL7808226 0.84 USP1 (1.00) USP1USP19WDR48USP2USP8
SCHEMBL29629183 0.84 USP1 (1.00) USP1USP19WDR48USP2USP8
SCHEMBL7808446 0.83 USP1 (0.72) USP1USP19WDR48USP2USP8
SCHEMBL19220486 0.78 USP1 (0.82) USP1USP19WDR48USP2USP8
SCHEMBL7811858 0.78 USP1 (0.67) USP1USP19WDR48USP2USP8
SCHEMBL19220487 0.77 USP1 (0.67) USP1USP19WDR48USP2USP8
SCHEMBL29493043 0.76 USP1 (1.00) USP1USP19WDR48USP2USP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0876356-B1 USE OF TRICYCLIC 1,4-DIHYDRO-1,4-DIOXO-1H-NAPHTHALENE DERIVATIVES, RESULTING NOVEL COMPOUNDS AND THERAPEUTICAL USE THEREOF INNOTHERA SA LAB (FR) 2001-10-31 EP claimed
US-9725425-B1 Compounds and methods for treating cancer DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-08-08 US disclosed
EP-0876356-B1 USE OF TRICYCLIC 1,4-DIHYDRO-1,4-DIOXO-1H-NAPHTHALENE DERIVATIVES, RESULTING NOVEL COMPOUNDS AND THERAPEUTICAL USE THEREOF INNOTHERA SA LAB (FR) 2001-10-31 EP disclosed
US-6262095-B1 TREATMENT OF ILLNESS ASSOCIATED WITH AN ALTERATION IN VENOUS FUNCTION AND/OR INFLAMMATORY EDEMA LABORATOIRE INNOTHERA (FR) 2001-07-17 US disclosed
EP-0876356-A1 USE OF TRICYCLIC 1,4-DIHYDRO-1,4-DIOXO-1H-NAPHTHALENE DERIVATIVES, RESULTING NOVEL COMPOUNDS AND THERAPEUTICAL USE THEREOF LABORATOIRE INNOTHERA Société Anonyme (FR) 1998-11-11 EP disclosed
WO-1997021684-A1 USE OF TRICYCLIC 1,4-DIHYDRO-1,4-DIOXO-1H-NAPHTHALENE DERIVATIVES, RESULTING NOVEL COMPOUNDS AND THERAPEUTICAL USE THEREOF LABORATOIRE INNOTHERA, SOCIETE ANONYME (FR) 1997-06-19 WO disclosed